202 related articles for article (PubMed ID: 16530416)
1. Retinoic acid metabolism blocking agents (RAMBAs) for treatment of cancer and dermatological diseases.
Njar VC; Gediya L; Purushottamachar P; Chopra P; Vasaitis TS; Khandelwal A; Mehta J; Huynh C; Belosay A; Patel J
Bioorg Med Chem; 2006 Jul; 14(13):4323-40. PubMed ID: 16530416
[TBL] [Abstract][Full Text] [Related]
2. Cytochrome p450 retinoic acid 4-hydroxylase inhibitors: potential agents for cancer therapy.
Njar VC
Mini Rev Med Chem; 2002 Jun; 2(3):261-9. PubMed ID: 12370067
[TBL] [Abstract][Full Text] [Related]
3. Novel retinoic acid metabolism blocking agents endowed with multiple biological activities are efficient growth inhibitors of human breast and prostate cancer cells in vitro and a human breast tumor xenograft in nude mice.
Patel JB; Huynh CK; Handratta VD; Gediya LK; Brodie AM; Goloubeva OG; Clement OO; Nanne IP; Soprano DR; Njar VC
J Med Chem; 2004 Dec; 47(27):6716-29. PubMed ID: 15615521
[TBL] [Abstract][Full Text] [Related]
4. Prospective teratology of retinoic acid metabolic blocking agents (RAMBAs) and loss of CYP26 activity.
McCaffery P; Simons C
Curr Pharm Des; 2007; 13(29):3020-37. PubMed ID: 17979744
[TBL] [Abstract][Full Text] [Related]
5. Molecular recognition of CYP26A1 binding pockets and structure-activity relationship studies for design of potent and selective retinoic acid metabolism blocking agents.
Sun B; Song S; Hao CZ; Huang WX; Liu CC; Xie HL; Lin B; Cheng MS; Zhao DM
J Mol Graph Model; 2015 Mar; 56():10-9. PubMed ID: 25541526
[TBL] [Abstract][Full Text] [Related]
6. Design, synthesis, and biological evaluation of amide imidazole derivatives as novel metabolic enzyme CYP26A1 inhibitors.
Sun B; Liu K; Han J; Zhao LY; Su X; Lin B; Zhao DM; Cheng MS
Bioorg Med Chem; 2015 Oct; 23(20):6763-73. PubMed ID: 26365710
[TBL] [Abstract][Full Text] [Related]
7. Synthesis of LIAZAL, a retinoic acid metabolism blocking agent (RAMBA) with potential clinical applications in oncology and dermatology.
Freyne E; Raeymaekers A; Venet M; Sanz G; Wouters W; De Coster R; Wauwe JV
Bioorg Med Chem Lett; 1998 Feb; 8(3):267-72. PubMed ID: 9871667
[TBL] [Abstract][Full Text] [Related]
8. The emerging role of retinoids and retinoic acid metabolism blocking agents in the treatment of cancer.
Miller WH
Cancer; 1998 Oct; 83(8):1471-82. PubMed ID: 9781940
[TBL] [Abstract][Full Text] [Related]
9. Effect of NADPH-cytochrome P450 reductase on all-trans-retinoic acid efficacy and cytochrome P450 26A1 expression in human myeloid leukaemia HL-60 cells.
Hu L; Lv JF; Zhuo W; Zhang CM; Zhou HH; Fan L
J Pharm Pharmacol; 2016 Sep; 68(9):1193-202. PubMed ID: 27366899
[TBL] [Abstract][Full Text] [Related]
10. Inhibitory effects of retinoic acid metabolism blocking agents (RAMBAs) on the growth of human prostate cancer cells and LNCaP prostate tumour xenografts in SCID mice.
Huynh CK; Brodie AM; Njar VC
Br J Cancer; 2006 Feb; 94(4):513-23. PubMed ID: 16449997
[TBL] [Abstract][Full Text] [Related]
11. Role of Retinoic Acid-Metabolizing Cytochrome P450s, CYP26, in Inflammation and Cancer.
Stevison F; Jing J; Tripathy S; Isoherranen N
Adv Pharmacol; 2015; 74():373-412. PubMed ID: 26233912
[TBL] [Abstract][Full Text] [Related]
12. All trans retinoic acid and cancer.
Siddikuzzaman ; Guruvayoorappan C; Berlin Grace VM
Immunopharmacol Immunotoxicol; 2011 Jun; 33(2):241-9. PubMed ID: 20929432
[TBL] [Abstract][Full Text] [Related]
13. all-trans-Retinoic acid-induced expression and regulation of retinoic acid 4-hydroxylase (CYP26) in human promyelocytic leukemia.
Ozpolat B; Mehta K; Tari AM; Lopez-Berestein G
Am J Hematol; 2002 May; 70(1):39-47. PubMed ID: 11994980
[TBL] [Abstract][Full Text] [Related]
14. Murine toxicology and pharmacokinetics of novel retinoic acid metabolism blocking agents.
Patel JB; Khandelwal A; Chopra P; Handratta VD; Njar VC
Cancer Chemother Pharmacol; 2007 Nov; 60(6):899-905. PubMed ID: 17345084
[TBL] [Abstract][Full Text] [Related]
15. All-trans-retinoic acid modulation of drug-metabolizing enzyme activities: investigation with selective metabolic drug probes.
Adedoyin A; Stiff DD; Smith DC; Romkes M; Bahnson RC; Day R; Hofacker J; Branch RA; Trump DL
Cancer Chemother Pharmacol; 1998; 41(2):133-9. PubMed ID: 9443626
[TBL] [Abstract][Full Text] [Related]
16. Synthesis and CYP26A1 inhibitory activity of novel methyl 3-[4-(arylamino)phenyl]-3-(azole)-2,2-dimethylpropanoates.
Gomaa MS; Lim AS; Lau SC; Watts AM; Illingworth NA; Bridgens CE; Veal GJ; Redfern CP; Brancale A; Armstrong JL; Simons C
Bioorg Med Chem; 2012 Oct; 20(20):6080-8. PubMed ID: 22989911
[TBL] [Abstract][Full Text] [Related]
17. Novel retinoic acid metabolism blocking agents have potent inhibitory activities on human breast cancer cells and tumour growth.
Patel JB; Mehta J; Belosay A; Sabnis G; Khandelwal A; Brodie AM; Soprano DR; Njar VC
Br J Cancer; 2007 Apr; 96(8):1204-15. PubMed ID: 17387344
[TBL] [Abstract][Full Text] [Related]
18. 3-[6-(2-Dimethylamino-1-imidazol-1-yl-butyl)-naphthalen-2-yloxy]-2,2-dimethyl-propionic acid as a highly potent and selective retinoic acid metabolic blocking agent.
Mulvihill MJ; Kan JL; Cooke A; Bhagwat S; Beck P; Bittner M; Cesario C; Keane D; Lazarescu V; Nigro A; Nillson C; Panicker B; Smith V; Srebernak M; Sun FL; O'Connor M; Russo S; Fischetti G; Vrkljan M; Winski S; Castelhano AL; Emerson D; Gibson NW
Bioorg Med Chem Lett; 2006 May; 16(10):2729-33. PubMed ID: 16504501
[TBL] [Abstract][Full Text] [Related]
19. All-trans-retinoic acid 4-hydroxylation in human liver microsomes: in vitro modulation by therapeutic retinoids.
Nadin L; Murray M
Br J Clin Pharmacol; 1996 Jun; 41(6):609-12. PubMed ID: 8799529
[TBL] [Abstract][Full Text] [Related]
20. [All-trans retinoic acid (ATRA) in prevention and cancer therapy].
Hoffman E; Mielicki WP
Postepy Hig Med Dosw (Online); 2010 Jun; 64():284-90. PubMed ID: 20558866
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
